02 Jul Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack?
A cell therapy approach improved patients' quality of life after a heartattack; plans for Phase 3 trials are underway.
Press clips
02 Jun CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality
Matthieu de Kalbermatten, CEO of CellProthera, discusses how new board appointments, manufacturing automation, and global clinical expertise are shaping the company's strategy to advance ProtheraCytes® toward late stage development and future commercialisation.
05 May Transendocardial Cell Delivery In Post‑Acute Myocardial Infarction
Myocardial infarction (MI) remains a leading cause of heart failure worldwide despite major advances in reperfusion and pharmacologic therapy.
16 Apr Why A Cell Therapy CEO Waited Until Phase III To Outsource
Sometimes, you have to go it alone. For a while, at least.
15 Apr Manufacturing Cell and Gene Therapies: Getting Advanced Therapies into Patients
Biopharmaceutical companies, regulators, and other stakeholders are aligned on the need to accelerate cell and gene therapy (CGT) development...
19 Mar CellProthera sets the scene for Phase III stem cell therapy trial
The biotech will soon evaluate the safety and efficacy of its regenerative cardiovascular stem cells, coined ProtheraCytes, in a Phase III trial.
04 Oct Drug TARGET REVIEW: Cell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
02 Sep CellProthera inches closer to Phase III trial for heart attack cell therapy
Speaking at a press conference, CellProthera’s CEO said the company is moving into the final phase of clinical development for its product.
31 Aug Euro Health Leaders: Navigating the Challenges of Autologous Cell Therapy Production
Revolutionizing Cardiac Regeneration.
11 Jul CellProthera and BioCardia Collaborate on Phase 2 Trial of ProtheraCytes to Treat AMI
July 8, 2024—France-based CellProthera and BioCardia, Inc., which is headquartered in California, announced findings from the collaborative phase 2 trial of CellProthera’s ProtheraCytes for the treatment of acute myocardial infarction (AMI). Additionally, the companies noted they plan to continue the collaboration into phase 3.